RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, is featured in a recent Cantor Fitzgerald research brief. Noting that the stock “looks even more interesting post solid quarter and ahead of potential strategic acquisition,” the research brief reiterated its previous Overweight (“OW”) rating and 12-month price target of $6 for RVL Pharmaceutical shares, stating that RVLP’s commercial opportunities continue to be underappreciated and that upward earnings estimate revisions should drive the stock higher. The brief noted that RVLP’s prescription eye drop, UPNEEQ 0.1%, had been selected the winner in the professional treatment category as “Best Eye Drop for Drooping Lids” in the NewBeauty annual beauty awards, and that the company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden RVLP’s portfolio and leverage the field force investment.

“RVLP said it is in advanced discussions with certain companies that it could potentially partner with or acquire to support growth and integrate into its infrastructure with meaningful synergies,” stated the Cantor Fitzgerald report. “RVLP [also] reported second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, year over year, respectively. RVLP highlighted its lower baseline of operating expenses. It streamlined its operating expenses to extend its cash runway, optimize its marketing mix and support strategic business development. This streamlining had a modest unfavorable impact on sales during the quarter. And at 6/30/23, the company had cash and cash equivalents of $19.2 million and senior secured indebtedness with aggregate principal maturities of $70.7 million.”

To view the full press release, visit https://ibn.fm/r81W9

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first nonsurgical treatment option approved by the FDA for acquired blepharoptosis. For additional information about this company, please visit www.RVLPharma.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork